Delayed niacin skin flush response and cognitive impairment in Late‐Life Depression

Yijia Chen, You Wu, Dandan Wang, Yang Yang, Qianqian Guo, Qi Qiu, Chunlin Wan, Xia LiAlzheimer 2025 · DOI

TL;DR

This study investigates the niacin skin flush response (NSFR) as a potential biomarker for cognitive impairment (CI) in late-life depression (LLD). Researchers found that LLD patients with CI exhibit a delayed NSFR, which can effectively distinguish them from LLD patients without CI and even predict future cognitive decline.

What Problem Does This Paper Address?

Late-life depression (LLD) is a significant concern, especially when accompanied by cognitive impairment (CI). This combination is a known risk factor for developing Alzheimer's disease (AD), but the underlying biological mechanisms are not fully understood. While altered NSFR has been observed in other neurological and psychiatric conditions, its role in LLD with CI has been largely unexplored. This paper aims to bridge this gap by examining whether NSFR can serve as a useful indicator for identifying cognitive issues in LLD patients and potentially predicting their future cognitive trajectory.

Methods

The researchers employed a modified method to assess the niacin skin flush response (NSFR). The rate of NSFR was quantified using LogEC50. Cognitive function was evaluated using the Chinese version of the Montreal Cognitive Assessment (MoCA). The study involved a comparison of NSFR and cognitive scores across four groups: LLD with CI, LLD without CI, Alzheimer's Disease (AD) patients, and healthy controls (HCs). Multivariate analysis of variance (MANOVA) was used to account for demographic differences between groups. To assess the predictive power of NSFR, logistic regression models were built, and receiver-operating characteristic (ROC) curve analysis was performed. A six-month follow-up was conducted to evaluate the predictive value of baseline NSFR on cognitive outcomes.

Datasets

The study utilized data from:

  • 86 patients diagnosed with Late-Life Depression (LLD), further divided into:
  • 46 LLD patients with Cognitive Impairment (CI)
    • 40 LLD patients without CI
  • 20 patients diagnosed with Alzheimer's Disease (AD)
  • 32 Healthy Controls (HCs)

The cognitive function of these participants was assessed using the Chinese version of the Montreal Cognitive Assessment (MoCA).

Key Insights and Ideas

  • NSFR as a potential biomarker for CI in LLD: The study highlights that a delayed NSFR is not just a physiological quirk but a meaningful indicator associated with cognitive deficits in LLD.
  • Distinguishing CI within LLD: The NSFR appears to be sensitive enough to differentiate between LLD patients who have cognitive impairment and those who do not, suggesting it could be a valuable screening tool.
  • Predictive power for cognitive decline: The research indicates that an abnormal NSFR at the outset of LLD can forecast poorer cognitive outcomes down the line, opening doors for early intervention strategies.
  • Bridging the gap to AD research: By identifying a potential biological marker linked to CI in LLD, this work could shed light on the early stages of neurodegenerative processes that might precede or contribute to AD.

Key Results

  • LLD patients with CI showed significantly elevated LogEC50 levels (indicating a delayed NSFR) compared to both LLD patients without CI (p < 0.05) and healthy controls (p < 0.05).
  • No significant differences in LogEC50 were found between LLD patients without CI and HCs, nor between LLD with CI and AD patients.
  • ROC analysis demonstrated that LogEC50 could effectively distinguish between LLD with CI and LLD without CI.
  • Six-month follow-up data confirmed that baseline LogEC50 levels could effectively predict cognitive outcomes in LLD patients.

Limitations and Future Work

The authors acknowledge that while NSFR shows promise, further research is needed to fully understand the underlying mechanisms connecting delayed NSFR to CI in LLD. The study's findings suggest that NSFR could serve as a potential biomarker for LLD with CI, and a delayed NSFR at baseline may predict poorer cognitive outcomes. These insights open new avenues for research into the mechanisms underlying CI in LLD and offer fresh perspectives on potential therapeutic targets.

Summary updated

Abstract

LLD with CI exhibited a delayed NSFR. Delayed NSFR proved effective in distinguishing cognitive impairment in LLD, suggesting that NSFR could serve as a potential biomarker for LLD with CI. Furthermore, in patients with LLD, a delayed NSFR at baseline predicts poorer cognitive outcomes. These insights open new avenues for research into the mechanisms underlying CI in LLD and offer fresh perspectives on potential therapeutic targets.
BibTeX
@inproceedings{chen2025delayed,
  author = {Yijia Chen and You Wu and Dandan Wang and Yang Yang and Qianqian Guo and Qi Qiu and Chunlin Wan and Xia Li},
  title = {{Delayed niacin skin flush response and cognitive impairment in Late‐Life Depression}},
  booktitle = {Alzheimer},
  year = {2025},
  doi = {10.1002/alz70857\_097465},
}
Figure